Researchers found that naturally-occurring CD7-negative T cells avoid self-destruction and are good effectors in CAR T therapy for T cell blood cancers. Deanna earned their PhD in cellular biology ...

Promising Cell Therapy Offers Hope for Relapsed or Refractory T-Cell Leukaemia Oct. 7, 2024 — Fratricide-resistant CD7 CAR-T therapy by NUS proves effective in treating relapsed or refractory T-cell ...

Despite their initial efficient response to induction chemotherapy, relapse remains frequent in patients with T-cell acute lymphoblastic leukemia (T-ALL), an aggressive malignancy of immature T ...

Genomic DNA isolated from CUTLL1 cells and from the corresponding primary T-cell lymphoblastic lymphoma ... of CD4 and CD8 as well as CD2, CD5, CD7, surface CD3 and TCRαβ (Figure 1).

Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced the ...